S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:KZIA

Kazia Therapeutics (KZIA) Stock Price, News & Analysis

$0.23
+0.01 (+4.49%)
(As of 03/18/2024 ET)
Today's Range
$0.22
$0.24
50-Day Range
$0.20
$0.40
52-Week Range
$0.19
$1.68
Volume
226,853 shs
Average Volume
842,590 shs
Market Capitalization
$3.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Kazia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
760.2% Upside
$2.00 Price Target
Short Interest
Healthy
4.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Kazia Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.40) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

KZIA stock logo

About Kazia Therapeutics Stock (NASDAQ:KZIA)

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

KZIA Stock Price History

KZIA Stock News Headlines

KZIA Apr 2024 2.500 call
Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Update
The only AI company you should be looking at
This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Kazia Therapeutics Limited
Kazia Therapeutics Ltd. ADR
Viking Therapeutics, Inc. Common Stock (VKTX)
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
Kazia Therapeutics Announces Registered Direct Offering - Quick Facts
See More Headlines
Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/18/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KZIA
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+760.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20,000.00
Book Value
$0.50 per share

Miscellaneous

Free Float
16,178,000
Market Cap
$3.80 million
Optionable
Optionable
Beta
2.09
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

KZIA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kazia Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KZIA shares.
View KZIA analyst ratings
or view top-rated stocks.

What is Kazia Therapeutics' stock price target for 2024?

1 equities research analysts have issued 12 month price objectives for Kazia Therapeutics' shares. Their KZIA share price targets range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 760.2% from the stock's current price.
View analysts price targets for KZIA
or view top-rated stocks among Wall Street analysts.

How have KZIA shares performed in 2024?

Kazia Therapeutics' stock was trading at $0.4395 at the beginning of the year. Since then, KZIA stock has decreased by 47.1% and is now trading at $0.2325.
View the best growth stocks for 2024 here
.

Are investors shorting Kazia Therapeutics?

Kazia Therapeutics saw a increase in short interest in February. As of February 29th, there was short interest totaling 765,100 shares, an increase of 1,566.9% from the February 14th total of 45,900 shares. Based on an average trading volume of 680,600 shares, the short-interest ratio is presently 1.1 days.
View Kazia Therapeutics' Short Interest
.

What other stocks do shareholders of Kazia Therapeutics own?
Who are Kazia Therapeutics' major shareholders?

Kazia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (15.15%), Platinum Investment Management Ltd. (11.15%), Hsbc Holdings PLC (0.61%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KZIA) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners